Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

PTGX Protagonist Therapeutics, Inc
$104.75 4.23% +4.25
Notify me if price changes either direction
Interactive Brokers Logotype

Buy PTGX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 6.4B
Enterprise value 5.8B
Trailing PE 139.51515
Forward PE -227.6904
PEG Ratio -227.6904
Enterprise to EBITDA -36.671
Enterprise to revenue 124.994
Price to book MRQ 10.065153
Price to sales TTM 137.09944

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 46.0M
EBITDA -156847008
Diluted EPS TTM -2.05
Total Cash (MRQ) 567.4M
Current ratio (MRQ) 12.71
Operating Cash Flow (TTM) 57.7M

PTGX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent PTGX News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.